Skip to main content
. Author manuscript; available in PMC: 2019 Jan 29.
Published in final edited form as: J Parkinsons Dis Alzheimers Dis. 2018 May 21;5(1):10.13188/2376-922X.1000025. doi: 10.13188/2376-922X.1000025

Figure 1:

Figure 1:

Effects of PPAR agonist treatments on i.e. STZ-aIterations in neuroglial and inflammatory markers. Postnatal Day 3 (P3) Long Evans rat pups were treated with i.e. STZ or vehicle. Frontal lobe slice cultures generated 24 hours later were maintained for 72 hours and treated daily with L165,041 (PPAR-δ) + F-L-Leu (PPAR-γ) agonists or vehicle. Protein homogenates were used to measure (A) Hu (neuronal marker), (B) common leukocyte antigen-microglia (CD45), (C) myelin-associated glycoprotein-1 (MAG-1), and (D) glial fibrillary acidic protein (GFAP) immunoreactivity with duplex ELISAs. Results were normalized to RPLPO. Data were analyzed by two-way ANOVA (Table 1). Significant post hoc test results are displayed.